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Partial virological response to nucleos(t)ide analogues in naı¨ve
patients with chronic hepatitis B: From guidelines to ﬁeld practiceq
Pietro Lampertico*
First Division of Gastroenterology, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena,
University of Milan, Via Francesco Sforza 35, 20122 Milan, ItalySee Article, pages 674–683According to the recent EASL HBV Clinical Practice
Guidelines, partial virological responders (PVR) to
nucleos(t)ide analogues (NUC) are patients with more
than 1 log decline of viremia compared to baseline but
still have detectable serum levels of HBV DNA by
real-time PCR assay (>10–15 IU/ml) at Week 24 or
48, depending on the genetic barrier of the anti-HBV
drug [1]. Though the prevalence of partial virological
response according to this new deﬁnition is not known
exactly, the rates of patients with detectable HBV
DNA by sensitive assay, i.e. >60–80 IU/ml (equivalent
to approximately 300 or 400 copies/ml), at Week 24
for lamivudine (LMV) and telbivudine (LDT) and at
Week 48 for adefovir (ADV), entecavir (ETV) and ten-
ofovir (TDF) have been delineated in diﬀerent, indepen-
dent studies (see Figure).
The clinical relevance of NUC partial virological
response relates to the high risk these patients face of
developing resistance to long-term anti-HBV treatment,
particularly when ﬁrst (LMV) and second generation
(LDT, ADV) drugs are involved [1]. Conversely, for
PVR on third generation NUCs like ETV and TDF,
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emtric´itabine.therapy, the association between residual viremia at
Week 48 and secondary treatment failure during
follow-up has not been fully established [1]. Despite
the strong rationale for adapting antiviral therapy, at
least for selected NUCs, evidence-based algorithms for
rescuing these patients have not been developed, apart
from expert opinions. The paper by Reijenders et al.
in this issue of the Journal is the ﬁrst to evaluate the eﬃ-
cacy of ETV in NUC- naı¨ve partial virological respond-
ers to ADV monotherapy [2].
Twenty-nine to 68% of the patients on LMV mono-
therapy were PVR at Week 24, showing an increased
risk of developing drug resistance in follow-up, thus
requiring early adaptation of antiviral therapy (see
Figure) [3,4]. To assess whether PVR to LMV would
beneﬁt by switching to LDT, 246 HBeAg-positive
and negative patients previously treated with LMV
for 3–12 months at the time of screening, with HBV
DNA >3 log copies/ml and compensated liver disease,
were randomized to switch to LDT treatment
(n = 122) or continue LMV (n = 124) for one year
[5]. The extent of HBV suppression at Week 24 was
greater in LDT-treated patients than in patients who
continued on LMV (mean 1.90 log copies/ml vs.
0.90 log copies/ml, p = 0.002) although HBV was
equally undetectable in the two groups (40% vs.
31%, p = 0.14). While these ﬁndings suggest a partial
beneﬁt of early adaptation, at least for the ﬁrst 24
weeks, LDT monotherapy might not be the best strat-
egy to manage PVR to LMV, because the two drugs
share a similar cross-resistance proﬁle despite LDT
having a slightly better genetic barrier to resistance
than LMV [1].Published by Elsevier B.V. All rights reserved.
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Figure. Rates of partial virological responders (PVR), deﬁned as patients with detectable HBV DNA by PCR assay at Week 24 for LMV and LDT and
Week 48 for ADV, ETV, TDF. Viremia was quantiﬁed by Roche Cobas Amplicor PCR assay with a lower detection limit of 300 copies/ml for LMV,
LDT and ETV and by Roche Cobas Taq-Man PCR assay with a lower detection limit of 400 copies/ml for TDF. Studies were not head-to-head. Baseline
HBV DNA was expressed as log copies/ml.
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HBeAg-negative patients (55 vs. 20%) showed detect-
able HBV DNA at Week 24 (see Figure) [4] and though
PVR had a well deﬁned increased risk of LDT resistance
at Week 104 [5], no studies that assess the best rescue
strategy in these patients, are available.
Of patients on ADV monotherapy, 37% of HBeAg-
negative patients and 87% of the HBeAg-positive
patients showed partial virological responses at Week
48 (see Figure) [6]. The 49% risk of developing ADV
resistance at Week 192 for HBeAg-negative patients
with >3 log copies/ml of HBV DNA at Week 48 was sig-
niﬁcantly higher than the 6% risk of those with lower
viremia [7], suggesting the need for early adaptation of
antiviral therapy in the former group. The management
of PVR to ADV has been investigated in 5 studies with
TDF, ETV or LDT as monotherapies. TDF emerges as
an option in these patients as partial virological
response to ADV reﬂects low potency of this drug rather
than the emergence of resistant strains. Among ADV
PVR at Week 48, viral suppression (<400 copies/ml
HBV DNA) was achieved at Week 96 in 82% of
HBeAg-positive and in all HBeAg-negative patients
who were switched to TDF monotherapy at Week 48
[8,9], suggesting that TDF suppressed HBV replication
in most ADV PVR within 48 weeks of therapy. Because
of its potency, high genetic barrier and diﬀerent cross-
resistance proﬁle, ETV was also assessed as a potential
rescue therapy for ADV PVR in two studies. This issue
of the Journal describes six LMV-naı¨ve, HBeAg-positive
patients with HBV DNA >5 log copies/ml after 17 (12–
31) months of ADV monotherapy, in the absence of
ADV-related mutations, who were switched to ETV1.0 mg [2]. Viral load, which was 7.1 (6.1–10.1) log cop-
ies/ml at baseline, declined by 3.4 (2.4–5.8) log copies/ml
after 48 weeks, with one patient only becoming PCR
negative at month 12, and no patient showing HBeAg
loss in the absence of virological breakthrough or ETV
resistance. Virological response to ETV rescue was sur-
prisingly lower than expected despite the reinforced dos-
age of 1.0 mg instead of 0.5 as recommended for LMV-
naı¨ve patients, the high genetic barrier of ETV and the
diﬀerent cross-resistance proﬁle of this drug compared
to ADV. These ﬁndings were challenged by a study pre-
sented at the AASLD 2008 meeting, where twenty-nine
patients with incomplete viral suppression on ADV,
deﬁned as failure to achieve a 2 log reduction of viral
load at Week 24 or HBV DNA undetectability at Week
48, were switched to ETV [10]. At baseline, median age
was 49 years, 61% were male, 55% HBeAg-positive,
median time on ADV prior to switching was 80 weeks
(16–237) and median HBV DNA was 4.4 (2.4–8.2) log
IU/ml. The rates of virological response, i.e. serum
HBV DNA <60–100 IU/ml, were 55, 77 and 82% after
24, 48 and 96 weeks of therapy, suggesting a satisfactory
response to ETV switch. The apparently contradictory
results of these two studies might depend on relevant
variables, like the deﬁnition of partial virological
response and more importantly, the baseline level of
HBV DNA at the time of switch, which was approxi-
mately 7 log copies/ml in the former study and 4.4 log
IU/ml in the latter. LDT could represent an alternative
approach to the management of ADV PVR because of
its potency, although a switch to a lower genetic barrier
drug may expose patients to developing drug resistance
in the long term. In a prospective controlled study, 46
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DNA of 9.5 log copies/ml, were treated with ADV for
24 weeks to be subsequently switched to LDT mono-
therapy [11]. The proportion of patients with undetect-
able viremia increased from 12% at the time of LDT
switch (Week 24) to 54% at Week 52, i.e. after 24 addi-
tional weeks of LDT, compared to an increase of HBV
DNA undectability rates from 12% to 40% in a parallel
group of 44 patients with similar baseline features who
continued ADV monotherapy. By exploratory analysis,
the 78% of ADV suboptimal responders, deﬁned by
HBV DNA level P3 log copies/ml at Week 24, who
switched from ADV to LDT, displayed an additional
reduction of 2.1 log copies/ml of HBV DNA between
Weeks 24 and 52, compared with 0.8 log copies/ml for
patients continuing ADV through Week 52, although
the proportion of HBV DNA PCR-negative patients
was similar between groups (42% vs. 24%; p = 0.11).
Ten to 33% of patients on ETV monotherapy for 48
weeks showed a partial virological response, i.e. HBV
DNA >300 copies/ml by Roche Cobas Amplicor PCR
assay (see Figure) [12,13]. Though there is no clear-cut
evidence that ETV PVR at Week 48 are likely to develop
resistance in the subsequent years, ETV-resistant strains
developed in two LMV-naı¨ve patients with incomplete
suppression at Week 48 [14,15], suggesting that even
partial virological response to a 3rd generation NUC
like ETV, entails a residual risk of secondary treatment
failure. Full papers assessing the best strategy to treat
these patients have not been published so far but a
recent abstract shed some light on this issue [16]. Among
236 patients with chronic hepatitis B receiving ETV
monotherapy for a mean of 68 weeks (53–126), 7
patients (3%) had suboptimal responses to ETV (<1
log HBV DNA reduction in 6 months), requiring a
switch to TDF monotherapy. All patients were Chinese,
5 LMV-naı¨ve, 5 males, and 5 HBeAg-positive with a
mean HBV DNA level of approximately 4 log copies/
ml and none with antiviral resistance at the time of
TDF switch. All patients achieved HBV DNA
<160 copies/ml within 24 weeks of TDF monotherapy
without evidence for a virological breakthrough during
a mean of 34.8 (16–76) weeks.
In the recently published Phase III study on TDF, the
48-week rates of partial virological response, i.e. the pro-
portion of patients with >400 copies/ml of HBV DNA
by Roche Cobas Taq-Man PCR assay, were 7% for
HBeAg-negative and 24% for HBeAg-positive patients
(see Figure) [6]. The clinical outcome of TDF PVR is
unknown, but no patient developed TDF resistance
through Week 96, the rates of HBV DNA suppression
progressively increased during the second year of ther-
apy, while patients with incomplete viral suppression
at Week 72, i.e. >400 copies/ml of HBV DNA, were
oﬀered a rescue therapy with add-on FTC [8,9]. The
28 HBeAg-positive patients (13 ADV-TDF and 15TDF-TDF) who started on combination therapy with
FTC and TDF, had a HBV DNA decline from 4.36 to
3.57 log copies/ml within 16 weeks of treatment,
whereas 4 (14%) patients only cleared HBV DNA [9].
While these data suggest a slow response to the nucleo-
side analogue in TDF PVR after 72 weeks of therapy,
the short duration of additional combination treatment
and the lack of an individual virological proﬁle from
patients who were rescued with FTC + TDF and from
those who continued on TDF monotherapy, does not
allow for any deﬁnitive conclusion.
In summary, with the EASL HBV Clinical Practice
Guidelines setting the stage for a new deﬁnition of
PVR, i.e. patients with detectable HBV DNA by real-
time PCR assay (>10–15 IU/ml) at Week 24 or 48, hep-
atologists are forced to reassess the eﬃcacy of currently
available therapeutics providing evidence-based studies
to improve the management of these patients. The risk
for PVR to develop resistance in the subsequent months
has been clearly demonstrated following LMV, LDT
and ADV, to such an extent that EASL suggested either
to switch to a more potent drug (ETV or TDF) or add a
more potent drug that does not share cross-resistance,
i.e. TDF to LMV or LDT, or ETV to ADV [1]. Con-
versely, the risk of secondary treatment failure for
patients with residual viremia at Week 48 following
compounds with high genetic barrier like ETV and
TDF, has not been demonstrated, though it is plausible
on virological grounds and suggested by preliminary
clinical data [14,15]. This is a relevant clinical issue both
in terms of added cost and uncertain safety data for add-
on strategy, as well as added risk of resistance in case of
switch to strategy or long-term maintained mono-
therapy. The uncertainty on this issue is reﬂected in
the EASL guidelines, where some of the experts sug-
gested to add the other drug in order to prevent resis-
tance in the long term, although the long-term safety
of ETV and TDF in combination is unknown [1], while
others suggested either switch to or continuation of
monotherapy. Alternative options include to delay from
Week 48 to Week 72 the time point for this therapeutic
decision or, on the basis of kinetics or pattern of serum
HBV DNA, stratify PVR at Week 48 according to the
risk of developing HBV resistance to third generation
NUCs like ETV and TDF, and deliver a prompt rescue
therapy to those PVR who do not show a progressive,
continuous decline of viremia [17]. Though the mecha-
nisms accounting for partial virological response to last
generation anti-HBV drugs in NUC- naı¨ve patients are
poorly understood, the longer time to undetectability
in patients with higher baseline viral load is a likely
explanation. To date, other poorly understood events
like intestinal absorption, cell entry and hepatocyte
phosphorylation rates of the drug may impact not only
virological response to the ﬁrst drug but also on that of
the rescue drug. Finally, the importance of the selection
P. Lampertico / Journal of Hepatology 50 (2009) 644–647 647of drug-resistant strains which is negligible for ETV or
TDF PVR in the registration trials, might be greater
in ﬁeld practice studies where patient adherence and
compliance may be suboptimal.
The study by Reijnders et al. in this issue of the Jour-
nal adds to the available evidence on the management of
NUC PVR, but more work is needed on issues like
assessing the rates of partial virological response to
ETV and TDF in clinical practice, risk of a ﬂat HBV
DNA kinetics, drug resistance, and validation of the
best antiviral algorithms. While results of ongoing clin-
ical trials focusing on the rescue strategy of PVR are
awaited, the EASL HBV Clinical Practice Guidelines
have proposed a rescue strategy for NUC PVR which
represents a clinically and virologically sound approach.References
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